•
New system combines Kaleido with Diabeloop’s
DBLG2 algorithm and Dexcom G7, with first commercial deliveries in Germany and
the Netherlands planned for later this summer
•
Enables insulin automation to be controlled
directly from the user’s smartphone, rather than a separate dedicated handset
•
Starting on Kaleido today with Diabeloop’s
DBLG1 algorithm is the fastest path to Kaleido with DBLG2 and Dexcom G7
____________________________________________________________________________________________________________
Utrecht,
the Netherlands — May 12, 2026
ViCentra, a European medical device
company commercializing the Kaleido insulin patch pump system, today announced the
commercial launch of its new smartphone-controlled hybrid closed loop system,
with first commercial deliveries in Germany and the Netherlands planned for
later this summer.
The new system brings together
Kaleido, the smallest, lightest and most precise insulin patch pump in its
class, with Diabeloop’s self-learning DBLG2 algorithm and Dexcom G7 Continuous Glucose
Monitoring (CGM) system to deliver a more streamlined hybrid closed loop
experience. Designed to fit more naturally into daily life, Kaleido is discreet,
intuitive and personalized, giving people with diabetes greater flexibility and
choice in how they manage their therapy.
The system enables hybrid closed loop
therapy to be controlled directly from the user’s smartphone, rather than a
separate dedicated handset. Dexcom G7 further enhances the experience with its
smaller, all-in-one sensor and transmitter, making the overall system more
streamlined and convenient to use.
Following a pilot launch in the
Netherlands, ViCentra is now moving into commercial execution in Germany and
the Netherlands. With the commercial version of the system now ready for
market, ViCentra will formally unveil the new system at the 60th DDG Diabetes Congress in Berlin, the annual
congress of the German Diabetes Association (Deutsche Diabetes Gesellschaft),
ahead of first deliveries later this summer.
“This is an important milestone for
ViCentra and an exciting step forward for people with diabetes in Germany and
the Netherlands,” said Tom Arnold, Chief Executive Officer of ViCentra.
“With Kaleido, DBLG2 and Dexcom G7, we are making automated insulin delivery
simpler, more flexible and easier to live with. It brings together smartphone
control, the latest CGM technology and Kaleido’s distinctive design in a way
that fits more naturally into everyday life.”
Starting on Kaleido today with
Diabeloop’s DBLG1 algorithm is the fastest path to Kaleido with DBLG2 and
Dexcom G7. This allows healthcare professionals to start therapy for people
with diabetes now and we’ll transition them smoothly to the new system when it
becomes available later this summer.
Over the past year, ViCentra has
expanded its commercial presence in Germany and the Netherlands, strengthened
its operational readiness, and continued building the capabilities needed to
support future growth in Europe and the U.S. The introduction of Kaleido with
Diabeloop’s DBLG2 algorithm and Dexcom G7 marks the next step in ViCentra’s
strategy to scale a differentiated insulin delivery platform and expand access
to automated insulin delivery. ViCentra will provide further updates on
availability and transition pathways as the launch approaches.
ViCentra will be exhibiting at the 60th
DDG Diabetes Congress in Berlin, Germany, from 13–15 May 2026 and welcomes
meetings with healthcare professionals, partners and other stakeholders
throughout the event.
– Ends –
For more information, please contact:
Optimum Strategic Communications
Zoe Bolt,
Katie Flint, Nellie Stephens
+44 (0) 203 882 9621
Email: vicentra@optimumcomms.com
About ViCentra
ViCentra is on a mission to improve
life with diabetes through empathetic innovation, simplicity, and design
excellence. The company develops and manufactures the Kaleido insulin patch
pump, a flexible, discreet, and beautifully crafted alternative to traditional
insulin pumps. Headquartered in Utrecht, the Netherlands, ViCentra is
expanding across Europe and preparing for U.S. market entry.
About Kaleido
Kaleido
is redefining the category of wearable insulin delivery as the first insulin
patch pump designed with the form, function, and simplicity of a lifestyle
product. Compact, featherlight, and discreet, Kaleido is designed with a focus
on personal technology rather than a traditional medical device. It is made
from premium materials and features customizable aluminum shells in ten color
options, enabling
It is the smallest, lightest, most
precise insulin patch pump in its class—delivering advanced, automated insulin
therapy through seamless integration with Diabeloop’s clinically validated
hybrid closed loop algorithms, DBLG1 and DBLG2.